文献速递免疫规划

离体抗原脉冲外周血单核细胞作为疫苗可产生强效持久抗感染免疫

Ex vivo antigen-pulsed PBMCs generate potent and long lasting immunity to infection when administered as a vaccine.
PubMed 文献 · Vaccine · 2017-01-06

研究以灭活土拉弗朗西斯菌抗原和肺炎链球菌疫苗Prevnar®13为模型,比较离体抗原脉冲外周血单核细胞(PBMC)替代树突状细胞(DC)作为疫苗的效果。结果表明PBMC可替代DC,鼻内途径优于静脉途径及直接注射Prevnar®13,且该策略提供更显著持久的保护性免疫并可作为多病原体疫苗平台。

要点

  • 离体抗原脉冲PBMC可替代DC作为疫苗,产生针对土拉弗朗西斯菌和肺炎链球菌的保护。
  • 鼻内给予抗原脉冲PBMC优于静脉途径,也优于直接肌内或鼻内注射Prevnar®13。
  • 该PBMC疫苗策略提供更显著持久的保护性免疫,并可作为多病原体疫苗平台。

核心结论

  • 离体抗原脉冲PBMC可替代DC作为疫苗,产生强效持久保护性免疫,并可作为多病原体疫苗平台。

研究设计与样本

  • 以灭活土拉弗朗西斯菌抗原为模型免疫原,先确定离体脉冲阶段能否用PBMC替代DC并提供抗土拉弗朗西斯菌感染保护。
  • 后续研究以肺炎链球菌疫苗Prevnar®13为脉冲阶段抗原,进行免疫和肺炎链球菌攻击。

主要发现

  • 在土拉弗朗西斯菌和Prevnar®13两种情况下,离体脉冲后回输抗原脉冲PBMC均可替代DC作为疫苗。
  • 肺炎链球菌免疫中,鼻内给予抗原脉冲PBMC优于静脉途径,也优于直接肌内或鼻内注射Prevnar®13。
  • 该PBMC疫苗策略提供更显著持久的保护性免疫反应,并可作为多病原体疫苗平台。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Numerous studies have demonstrated that administration of antigen (Ag)-pulsed dendritic cells (DCs) is an effective strategy for enhancing immunity to tumors and infectious disease organisms. However, the generation and/or isolation of DCs can require substantial time and expense. Therefore, using inactivated F. tularensis (iFt) Ag as a model immunogen, we first sought to determine if DCs could be replaced with peripheral blood mononuclear cells (PBMCs) during the ex-vivo pulse phase and still provide protection against Ft infection. Follow up studies were then conducted using the S. pneumoniae (Sp) vaccine Prevnar ®13 as the Ag in the pulse phase followed by immunization and Sp challenge. In both cases, we demonstrate that PBMCs can be used in place of DCs when pulsing with iFt and/or Prevnar ®13 ex vivo and re-administering the Ag-pulsed PBMCs as a vaccine. In addition, utilization of the i.n. route for Ag-pulsed PBMC administration is superior to use of the i.v. route in the case of Sp immunization, as well as when compared to direct injection of Prevnar ®13 vaccine i.m. or i.n. Furthermore, this PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism vaccine platform. The potential for this ex-vivo vaccine strategy to provide a simpler, less time consuming, and less expensive approach to DC-based vaccines and vaccination in general is also discussed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kumar S, Sunagar R, Pham G, et al. Ex vivo antigen-pulsed PBMCs generate potent and long lasting immunity to infection when administered as a vaccine. Vaccine. 2017. PMID: 28069362. doi:10.1016/j.vaccine.2016.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。